UPDATE 1-Santarus says appeals court ruling in Par patent suit

* In April, court ruled patents-in-suit were invalid

* Suit against Par over generic version of Zegerid

* Santarus shares up 8 pct in after-market trade

May 14 (BestGrowthStock) – Santarus Inc (SNTS.O: ) said it appealed a
U.S. district court ruling against it in a patent lawsuit
versus Par Pharmaceuticals (PRX.N: ), sending shares of the
specialty pharmaceutical company up 8 percent.

It filed its appeal with the U.S. Court of Appeals for the
Federal Circuit, Santarus said in a regulatory filing on
Friday.

In 2007, Santarus had filed two lawsuits in the Delaware
District Court against Par alleging infringement of patents
related to Par’s application to market the generic version of
Santarus’ heart-burn Zegerid.

In April, the court had ruled that the patents-in-suit were
invalid due to obviousness and also concluded that certain
asserted claims were invalid for lack of written description.
[ID:nSGE63D0EP]

Shares of Santarus rose 8 percent to $3.39 in after market
trade. They closed at $3.13 Friday on Nasdaq.

Stock Market Basics

(Reporting by Shailesh Kuber in Bangalore; Editing by
Aradhana Aravindan)

UPDATE 1-Santarus says appeals court ruling in Par patent suit